Clinical Trial Update: GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial from Chinese PLA General Hospital is evaluating eliglustat in combination with a CD30-targeted immunotherapy for CD30+ lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CD30-targeted immunotherapy
• Eliglustat (Eliglustat)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Lymphoma | Phase 1, Phase 2 | Status: RECRUITING